索拉菲尼联合复方斑螫胶囊对卵巢癌治疗的临床研究

Clinical Effect Analysis of Sorafenib Combined with Compound Banmao Capsule in the Treatment of Ovarian Cancer

目的:观察索拉菲尼联合复方斑螫胶囊治疗卵巢癌的临床疗效。方法:回顾性分析我院自2008年1月～2010年1月收治的60例卵巢癌患者,随机分为观察组及治疗组各30例,且均进行化疗处理。观察组即索拉菲尼联合复方斑螫胶囊组,对照组单用索拉菲尼,比较两组的总体疗效及不良反应发生情况。结果:观察组治疗结束后有效率为83.3%,稳定为16.7%,无进展0例。对照组治疗结束后有效率为60.0%,稳定为40.0%,无进展0例。两组总体疗效比较,具有统计学意义,P<0.05。不良反应以血色素下降、白细胞下降、周围神经炎及脱发,未出现严重的肝肾功能障碍。平均随访时间为14.6个月,随访期间3例复发,其中观察组1例(3.3%),对照组2例(6.7%)。结论:复方斑螫胶囊联合索拉菲治疗卵巢癌与单用索拉菲尼相比较,能够提高临床疗效,且复方斑螫胶囊服用方便、价格低廉、易推广。

Objective： Clinical effect analysis of sorafenib combined with compound Banmao capsule in the treatment of ovarian cancer.Methods： We retrospectively analyzed 60 cases patients who had ovarian cancers treated in our department from January 2008 to January 2010.The 60 cases were randomly divided into 2 groups of 30 cases in the control group which had been given Sorafenib combined with compound Banmao capsule and 30 cases in experimental group which had been given Sorafenib.Two groups were given chemotherapy.Contrast the therapeutic effects,influencing factor and complication.Results： The effective rate was 83.3%,stabliza rate was 16.7%,no progress was none in the experimental group,The effective rate was 60.0%,stabliza rate was 40.0%,no progress was none in the control group,There were significant differences of statistical significance（P0.05）.The level of haematochrome and white blood cell group was reduce,and peripheral neuritis and alopecie appeared and there was no serious complication.All patients were followed up,and the times were 14.6 month,relapse 3 cases between control groups（3.3%） and in the experimental group（6.7%）.Conclusion： Sorafenib combined with compound Banmao capsule in the treatment of ovarian cancer was effective.But traditional Chinese medicine is easier to be taken,and is cheaper,easy extension.